HBV DNA can bind to P53 protein and influence p53 transactivation in hepatoma cells

Biochemical and Biophysical Research Communications

Volumn 386, Issue 3, 2009, Pages 504-509

  Qu, Jianhui ^a   Lin, Jing ^a   Zhang, Shuhui ^a   Zhu, Zhi ^a   Ni, Canrong ^a   Zhang, Shunmin ^a   Gao, Hengjun ^b   Zhu, Minghua ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NATIONAL ENGINEERING CENTER FOR BIOCHIP AT SHANGHAI   (China)

Author keywords

DNA protein complex; Hepatitis B virus; Hepatoma; p53; Protein protein complex

Indexed keywords

PROTEIN P21; PROTEIN P53; VIRUS DNA;

ARTICLE; DNA PROTEIN COMPLEX; DNA VIRUS; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CARCINOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; VIRUS MUTANT; VIRUS REPLICATION; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL TRANSFORMATION, VIRAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA, VIRAL; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; PROMOTER REGIONS, GENETIC; RESPONSE ELEMENTS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 67650047728     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.06.081     Document Type: Article

References (40)

1. Farazi P.A., and DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6 (2006) 674-687
2. Hussain S.P., Schwank J., Staib F., Wang X.W., and Harris C.C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26 (2007) 2166-2176
3. Feitelson M.A., Zhu M., Duan L.X., and London W.T. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8 (1993) 1109-1117
4. Liu X., Zhang S., Lin J., Zhang S., Feitelson M.A., Gao H., and Zhu M. Hepatitis B virus X protein mutants exhibit distinct biological activities in hepatoma Huh7 cells. Biochem. Biophys. Res. Commun. 373 (2008) 643-647
5. Liu X., Wang L., Zhang S., Lin J., Zhang S., Feitelson M.A., Gao H., and Zhu M. Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses. Carcinogenesis 29 (2008) 1207-1214
6. Dumble M.L., Croager E.J., Yeoh G.C., and Quail E.A. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis 23 (2002) 435-445
7. Lechel A., Holstege H., Begus Y., Schienke A., Kamino K., Lehmann U., Kubicka S., Schirmacher P., Jonkers J., and Rudolph K.L. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology 132 (2007) 1465-1475
8. Soini Y., Chia S.C., Bennett W.P., Groopman J.D., Wang J.S., DeBenedetti V.M., Cawley H., Welsh J.A., Hansen C., Bergasa N.V., Jones E.A., DiBisceglie A.M., Trivers G.E., Sandoval C.A., Calderon I.E., Munoz Espinosa L.E., and Harris C.C. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 17 (1996) 1007-1012
9. Stahler F., and Roemer K. Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53. Oncogene 17 (1998) 3507-3512
10. Ueda H., Ullrich S.J., Gangemi J.D., Kappel C.A., Ngo L., Feitelson M.A., and Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 9 (1995) 41-47
11. Zhu M., London W.T., Duan L.X., and Feitelson M.A. The value of hepatitis B x antigen as a prognostic marker in the development of hepatocellular carcinoma. Int. J. Cancer 55 (1993) 571-576
12. Feitelson M.A., Ranganathan P.N., Clayton M.M., and Zhang S.M. Partial characterization of the woodchuck tumor suppressor, p53, and its interaction with woodchuck hepatitis virus X antigen in hepatocarcinogenesis. Oncogene 15 (1997) 327-336
13. Feitelson M.A., and Duan L.X. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am. J. Pathol. 150 (1997) 1141-1157
14. Santella R.M., Zhang Y.J., Chen C.J., Hsieh L.L., Lee C.S., Haghighi B., Yang G.Y., Wang L.W., and Feitelson M. Immunohistochemical detection of aflatoxin B1-DNA adducts and hepatitis B virus antigens in hepatocellular carcinoma and nontumorous liver tissue. Environ. Health Perspect. 99 (1993) 199-202
15. Lyakhov I.G., Krishnamachari A., and Schneider T.D. Discovery of novel tumor suppressor p53 response elements using information theory. Nucleic Acids Res. 36 (2008) 3828-3833
16. Wei C.L., Wu Q., Vega V.B., Chiu K.P., Ng P., Zhang T., Shahab A., Yong H.C., Fu Y., Weng Z., Liu J., Zhao X.D., Chew J.L., Lee Y.L., Kuznetsov V.A., Sung W.K., Miller L.D., Lim B., Liu E.T., Yu Q., Ng H.H., and Ruan Y. A global map of p53 transcription-factor binding sites in the human genome. Cell 124 (2006) 207-219
17. Smeenk L., van Heeringen S.J., Koeppel M., van Driel M.A., Bartels S.J., Akkers R.C., Denissov S., Stunnenberg H.G., and Lohrum M. Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res. 36 (2008) 3639-3654
18. Funk W.D., Pak D.T., Karas R.H., Wright W.E., and Shay J.W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12 (1992) 2866-2871
19. Xiao G., White D., and Bargonetti J. p53 binds to a constitutively nucleosome free region of the mdm2 gene. Oncogene 16 (1998) 1171-1181
20. Boehden G.S., Baumann C., Siehler S., and Wiesmuller L. Wild-type p53 stimulates homologous recombination upon sequence-specific binding to the ribosomal gene cluster repeat. Oncogene 24 (2005) 4183-4192
21. Mietz J.A., Unger T., Huibregtse J.M., and Howley P.M. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11 (1992) 5013-5020
22. Kley N., Chung R.Y., Fay S., Loeffler J.P., and Seizinger B.R. Repression of the basal c-fos promoter by wild-type p53. Nucleic Acids Res. 20 (1992) 4083-4087
23. Ono Y., Onda H., Sasada R., Igarashi K., Sugino Y., and Nishioka K. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res. 11 (1983) 1747-1757
24. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., and Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1 (1992) 45-49
25. Dignam J.D., Lebovitz R.M., and Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11 (1983) 1475-1489
26. Prusty B.K., and Das B.C. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int. J. Cancer 113 (2005) 951-960
27. Crow M., Deng T., Addley M., and Brownlee G.G. Mutational analysis of the influenza virus cRNA promoter and identification of nucleotides critical for replication. J. Virol. 78 (2004) 6263-6270
28. Acosta R., Montanez C., Fuentes-Mera L., Gonzalez E., Gomez P., Quintero-Mora L., Mornet D., Alvarez-Salas L.M., and Cisneros B. Dystrophin Dp71 is required for neurite outgrowth in PC12 cells. Exp. Cell Res. 296 (2004) 265-275
29. Chai C.Y., Huang Y.C., Hung W.C., Kang W.Y., and Chen W.T. Arsenic salt-induced DNA damage and expression of mutant p53 and COX-2 proteins in SV-40 immortalized human uroepithelial cells. Mutagenesis 22 (2007) 403-408
30. Tzeng Y.J., Zimmermann C., Guhl E., Berg B., Avantaggiati M.L., and Graessmann A. SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors. Oncogene 16 (1998) 2103-2114
31. Hsieh J.L., Wu C.L., Lee C.H., and Shiau A.L. Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. Clin. Cancer Res. 9 (2003) 338-345
32. Vollmer C.M., Ribas A., Butterfield L.H., Dissette V.B., Andrews K.J., Eilber F.C., Montejo L.D., Chen A.Y., Hu B., Glaspy J.A., McBride W.H., and Economou J.S. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res. 59 (1999) 4369-4374
33. Chen X., Cheung S.T., So S., Fan S.T., Barry C., Higgins J., Lai K.M., Ji J., Dudoit S., Ng I.O., Van De Rijn M., Botstein D., and Brown P.O. Gene expression patterns in human liver cancers. Mol. Biol. Cell 13 (2002) 1929-1939
34. Massimi P., Shai A., Lambert P., and Banks L. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene 27 (2008) 1800-1804
35. Heessen S., Leonchiks A., Issaeva N., Sharipo A., Selivanova G., Masucci M.G., and Dantuma N.P. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis. Proc. Natl. Acad. Sci. USA 99 (2002) 1532-1537
36. Truant R., Antunovic J., Greenblatt J., Prives C., and Cromlish J.A. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J. Virol. 69 (1995) 1851-1859
37. Dewantoro O., Gani R.A., and Akbar N. Hepatocarcinogenesis in viral Hepatitis B infection: the role of HBx and p53. Acta Med. Indones. 38 (2006) 154-159
38. Feitelson M.A., and Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 252 (2007) 157-170
39. Qu J.H., Zhu M.H., Lin J., Ni C.R., Li F.M., Zhu Z., and Yu G.Z. Effects of hepatitis B virus on p53 expression in hepatoma cell line SMMU-7721. World J. Gastroenterol. 11 (2005) 6212-6215
40. Meek D.W. Mechanisms of switching on p53: a role for covalent modification?. Oncogene 18 (1999) 7666-7675